ArticleClinical cancer research : an official journal of the American Association for Cancer Research2025
Next-Generation Sequencing-Based MSI Scoring Predicts Benefit in Mismatch Repair-Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D.
Jonathan D Schoenfeld et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.